Results 201 to 210 of about 45,700 (265)
Interplay of serum potassium and kidney function with finerenone in heart failure with mildly reduced or preserved ejection fraction: Findings from FINEARTS‐HF
European Journal of Heart Failure, EarlyView.CV, cardiovascular, HF, heart failure; K+, serum potassium; eGFR, estimated glomerular filtration rate. Aims
Finerenone improved heart failure (HF) outcomes in patients with heart failure and mildly reduced or preserved ejection fraction (HFmrEF/HFpEF). Clinical decision‐making around initiation of mineralocorticoid receptor antagonists often relies on João Pedro Ferreira, Muthiah Vaduganathan, Brian L. Claggett, Ian Kulac, John W. Ostrominski, Akshay S. Desai, Pardeep S. Jhund, Carolyn S.P. Lam, Michele Senni, Sanjiv J. Shah, Adriaan A. Voors, Bertram Pitt, Katja Rohwedder, Meike Brinker, Patrick Schloemer, John J. V. McMurray, Scott D. Solomon, Faiez Zannad +17 morewiley +1 more sourceGlobal patterns of polypharmacy after acute heart failure hospitalization: Prevalence and outcomes from the REPORT‐HF registry
European Journal of Heart Failure, EarlyView.Global patterns of polypharmacy after acute heart failure hospitalization. GDMT, guideline‐directed medical therapy; HF, heart failure. Aims
Polypharmacy, defined as the concurrent use of ≥5 medications, is prevalent among older adults with heart failure (HF).Wan Ting Tay, Tiew‐Hwa Katherine Teng, Wouter Ouwerkerk, John G.F. Cleland, Sean P. Collins, Christiane E. Angermann, Kenneth Dickstein, Ulf Dahlstrom, Anja Schweizer, Achim Obergfell, Kai‐Hang Yiu, Mathieu Ghadanfar, Mahmoud Hassanein, Qing‐Wen Ren, Wen‐Li Gu, Georg Ertl, Sergio V. Perrone, Gerasimos Filippatos, Carolyn S.P. Lam, Jasper Tromp +19 morewiley +1 more sourceA U‐shaped relationship between left ventricular ejection fraction and risk of worsening heart failure
European Journal of Heart Failure, EarlyView.A U‐shaped relationship between left ventricular ejection fraction (LVEF) and clinical outcomes. A U‐shaped relationship can be observed between LVEF, the primary outcome, and the cardiovascular‐related outcomes, including cardiovascular death and the risk of worsening heart failure (HF).Hao‐Chih Chang, Wei‐Ming Huang, Liang‐Yin Lin, Ching‐Wei Lee, Chih‐Hsueh Tseng, Wen‐Chung Yu, Hao‐Min Cheng, Chern‐En Chiang, Chen‐Huan Chen, Shih‐Hsien Sung +9 morewiley +1 more sourceEuropean Journal of Heart Failure consensus statement. Heart failure pharmacotherapy for patients with heart failure with reduced ejection fraction and concomitant atrial fibrillation: Review of evidence and call to action
European Journal of Heart Failure, EarlyView.Heart failure (HF) and atrial fibrillation (AF) are major global health challenges with rising prevalence and significant morbidity, mortality, and healthcare burden. Despite advances in HF management, AF remains a critical comorbidity that worsens outcomes and requires ad hoc treatment strategies, increasing the risk of non‐adherence and side effects. Mark Luedde, Stefan Agewall, Giuseppe Ambrosio, Antoni Bayes‐Genis, Claudio Borghi, Elisabetta Cerbai, Gheorghe A. Dan, Heinz Drexel, Péter Ferdinandy, Erik Lerkevang Grove, Juan Carlos Kaski, Roland Klingenberg, Joao Morais, William Parker, Mark C. Petrie, Bianca Rocca, Anne Grete Semb, Michele Senni, Christian Sohns, Patrick Sulzgruber, Juan Tamargo, Marco Metra, Michael Böhm, Dobromir Dobrev, Samuel Sossalla +24 morewiley +1 more sourceNeutrophil‐to‐lymphocyte ratio for risk stratification in acute myocarditis across the left ventricular ejection fraction spectrum
European Journal of Heart Failure, EarlyView.Illustration defining the criteria for high‐risk acute myocarditis (AM), incorporating haemodynamic compromise, life‐threatening arrhythmias, and reduced left ventricular ejection fraction (LVEF <40%). Neutrophil‐to‐lymphocyte ratio (NLR) ≥4 is an independent risk marker, including among patients with preserved LVEF (≥50%) at presentation, where ...Cristina Madaudo, Amitai Segev, Emanuele Bobbio, Chiara Baggio, Jonathan Schütze, Piero Gentile, Marta Sanguineti, Luca Monzo, Matteo Schettino, Emma Ferone, Ahmed Elsanhoury, Anan Younis, Matteo Palazzini, Adriana Ferroni, Valentina Giani, Matthew Sadler, Mohammad Albarjas, Leonardo Calò, Christian Lars Polte, Andrea Garascia, Stefano Figliozzi, Paul A. Scott, Ajay M. Shah, Alfredo Ruggero Galassi, Mauro Giacca, Gianfranco Sinagra, Entela Bollano, Theresa McDonagh, Carsten Tschöpe, Giuseppina Novo, Enrico Ammirati, Roy Beigel, Christoph Gräni, Marco Merlo, Pietro Ameri, Antonio Cannata, Daniel I. Bromage, CAIR Collaboration +37 morewiley +1 more sourceArtificial intelligence‐based echocardiographic assessment for monitoring disease progression in transthyretin cardiac amyloidosis
European Journal of Heart Failure, EarlyView.Artificial intelligence (AI)‐based estimation of stroke volume for risk prediction in amyloid transthyretin cardiomyopathy (ATTR‐CM). ATTRv, hereditary transthyretin amyloidosis; ATTRwt, wild‐type transthyretin amyloidosis; CI, confidence interval; HR, hazard ratio; IQR, interquartile range; LVOT‐VTI, left ventricular outflow tract velocity‐time ...Lucia Venneri, Alberto Aimo, Aldostefano Porcari, Irem Sezer, Adam Ioannou, Awais Sheikh, Josephine Mansell, Yousuf Razvi, Surabhi Bhaskar Iyer, Ana Martinez‐Naharro, Francesco Bandera, Sze Chi Lim, Matthew Frost, Justin Ezekowitz, Carolyn S.P. Lam, William Moody, Carol Whelan, Helen Lachmann, Ashutosh Wechelakar, Michele Emdin, Philip N. Hawkins, Scott David Solomon, Julian D. Gillmore, Marianna Fontana +23 morewiley +1 more source